Figure 3From: TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients Kaplan-Meier plots of progression-free survival (left) and overall survival (right) for serum concentrations of CA-125 after chemotherapy, TIMP-1 after chemotherapy, VEGF-165 before chemotherapy and VEGF-165 after chemotherapy. Dotted line: below median; solid-line: above median.Back to article page